MX 28701

Drug Profile

MX 28701

Alternative Names: MX 2870 1

Latest Information Update: 14 Oct 2003

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
  • Class Antineoplastics
  • Mechanism of Action Apoptosis stimulants; Retinoic acid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Cancer

Most Recent Events

  • 14 Oct 2003 No development reported - Preclinical for Cancer in USA (unspecified route)
  • 30 Apr 2003 Incyte Genomics is now called Incyte Corporation
  • 03 Mar 2003 Maxia Pharmaceuticals has been acquired by Incyte Genomics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top